BR112018074303A2 - composto, composição farmacêutica, métodos para tratamento de distúrbios e para degradação de proteínas-alvo, usos de um composto e de uma combinação, e, combinação. - Google Patents
composto, composição farmacêutica, métodos para tratamento de distúrbios e para degradação de proteínas-alvo, usos de um composto e de uma combinação, e, combinação.Info
- Publication number
- BR112018074303A2 BR112018074303A2 BR112018074303A BR112018074303A BR112018074303A2 BR 112018074303 A2 BR112018074303 A2 BR 112018074303A2 BR 112018074303 A BR112018074303 A BR 112018074303A BR 112018074303 A BR112018074303 A BR 112018074303A BR 112018074303 A2 BR112018074303 A2 BR 112018074303A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- combination
- treating disorders
- degradation
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610147.9A GB201610147D0 (en) | 2016-06-10 | 2016-06-10 | Novel compounds |
| PCT/EP2017/063909 WO2017211924A1 (fr) | 2016-06-10 | 2017-06-08 | Nouveaux composés |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018074303A2 true BR112018074303A2 (pt) | 2019-03-12 |
Family
ID=56894680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074303A BR112018074303A2 (pt) | 2016-06-10 | 2017-06-08 | composto, composição farmacêutica, métodos para tratamento de distúrbios e para degradação de proteínas-alvo, usos de um composto e de uma combinação, e, combinação. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190152946A1 (fr) |
| EP (1) | EP3468560A1 (fr) |
| JP (1) | JP2019517559A (fr) |
| KR (1) | KR20190017822A (fr) |
| CN (1) | CN109310693A (fr) |
| AU (1) | AU2017277596A1 (fr) |
| BR (1) | BR112018074303A2 (fr) |
| CA (1) | CA3025744A1 (fr) |
| GB (1) | GB201610147D0 (fr) |
| WO (1) | WO2017211924A1 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2971881T3 (es) | 2016-08-19 | 2024-06-10 | Beigene Switzerland Gmbh | Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer |
| TW201906866A (zh) | 2017-06-26 | 2019-02-16 | 英屬開曼群島商百濟神州有限公司 | 酸性鞘磷脂酶缺乏症患者中異常骨狀況的治療 |
| IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| EP3684366A4 (fr) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| WO2019140380A1 (fr) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019177902A1 (fr) * | 2018-03-10 | 2019-09-19 | Yale University | Modulateurs de protéolyse de btk et procédés d'utilisation |
| TWI846527B (zh) * | 2018-04-20 | 2024-06-21 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 一種多功能化合物、其製備方法及其在醫藥上的應用 |
| CN108794453A (zh) * | 2018-07-05 | 2018-11-13 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
| EP3817748A4 (fr) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | Ligands crbn tricycliques et leurs utilisations |
| EP3831811A4 (fr) | 2018-07-31 | 2022-04-20 | Fimecs, Inc. | Composé hétérocyclique |
| EP3856190A4 (fr) * | 2018-09-27 | 2022-09-21 | Dana Farber Cancer Institute, Inc. | Dégradation de fak ou fak et alk par conjugaison d'inhibiteurs de fak et d'alk avec des ligands de ligase e3 et procédés d'utilisation |
| EP3886904A4 (fr) | 2018-11-30 | 2022-07-13 | Kymera Therapeutics, Inc. | Agents de dégradation de kinases de type irak et leurs utilisations |
| SG11202109587TA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicle conjugates and uses thereof |
| WO2020191369A1 (fr) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
| AU2020253633A1 (en) | 2019-04-05 | 2021-11-04 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| WO2021011913A1 (fr) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Composés ciblant la protéine tau et procédés d'utilisation associés |
| JP2021024787A (ja) * | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| EP4006037A4 (fr) * | 2019-07-31 | 2023-12-13 | Fimecs, Inc. | Composé hétérocyclique |
| EP4076520A4 (fr) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| EP4076524A4 (fr) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| BR112022018678A2 (pt) | 2020-03-19 | 2022-11-01 | Kymera Therapeutics Inc | Degradadores de mdm2 e usos dos mesmos |
| WO2021237100A1 (fr) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Procédés d'administration ciblée de vésicules extracellulaires dans le poumon |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| WO2023147594A2 (fr) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080951A1 (es) | 2006-08-02 | 2008-09-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| CA2683318C (fr) | 2007-04-13 | 2012-10-30 | The Regents Of The University Of Michigan | Mimetiques smac diazobicyliques et utilisations de ceux-ci |
| US20140323346A1 (en) | 2011-11-21 | 2014-10-30 | Garvan Institute Of Medical Research | Binding agent |
| CN117736134A (zh) * | 2012-01-12 | 2024-03-22 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
| CA2882496C (fr) | 2012-08-23 | 2020-07-14 | The Regents Of The University Of Michigan | Inhibiteurs bivalents de proteines iap et methodes therapeutiques les utilisant |
| WO2014047024A1 (fr) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Antagonistes d'iap |
| WO2014055461A1 (fr) | 2012-10-02 | 2014-04-10 | Bristol-Myers Squibb Company | Antagonistes d'iap |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| WO2015092420A1 (fr) | 2013-12-20 | 2015-06-25 | Astex Therapeutics Limited | Composés hétérocycliques bicycliques et leurs utilisations thérapeutiques |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2017011590A1 (fr) * | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Modulateurs de protéolyse à base d'alanine et procédés d'utilisation associés |
-
2016
- 2016-06-10 GB GBGB1610147.9A patent/GB201610147D0/en not_active Ceased
-
2017
- 2017-06-08 BR BR112018074303A patent/BR112018074303A2/pt not_active Application Discontinuation
- 2017-06-08 US US16/308,542 patent/US20190152946A1/en not_active Abandoned
- 2017-06-08 KR KR1020187037976A patent/KR20190017822A/ko unknown
- 2017-06-08 AU AU2017277596A patent/AU2017277596A1/en not_active Abandoned
- 2017-06-08 WO PCT/EP2017/063909 patent/WO2017211924A1/fr unknown
- 2017-06-08 JP JP2018564391A patent/JP2019517559A/ja active Pending
- 2017-06-08 EP EP17728545.9A patent/EP3468560A1/fr not_active Withdrawn
- 2017-06-08 CA CA3025744A patent/CA3025744A1/fr not_active Abandoned
- 2017-06-08 CN CN201780035891.6A patent/CN109310693A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3468560A1 (fr) | 2019-04-17 |
| WO2017211924A1 (fr) | 2017-12-14 |
| JP2019517559A (ja) | 2019-06-24 |
| AU2017277596A1 (en) | 2018-12-06 |
| US20190152946A1 (en) | 2019-05-23 |
| CN109310693A (zh) | 2019-02-05 |
| GB201610147D0 (en) | 2016-07-27 |
| KR20190017822A (ko) | 2019-02-20 |
| CA3025744A1 (fr) | 2017-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018074303A2 (pt) | composto, composição farmacêutica, métodos para tratamento de distúrbios e para degradação de proteínas-alvo, usos de um composto e de uma combinação, e, combinação. | |
| BR112019002096A2 (pt) | composto, composição farmacêutica, método para tratar distúrbios e para degradar proteínas alvos, uso de um composto, combinação, e, uso de uma combinação | |
| BR112017008157A2 (pt) | polipeptídeos de fgf-21 modificados e usos dos mesmos | |
| BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112019006106A2 (pt) | formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio. | |
| CL2016002382A1 (es) | Derivados de quinoxalina útiles como moduladores de fgfr quinasa | |
| CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
| BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
| GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
| EA201891974A1 (ru) | Ингибиторы связывания белка wdr5 с белками | |
| BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
| BR112018011002A2 (pt) | variantes de fgf21 | |
| BR112017002001A2 (pt) | compostos e composição farmacêutica | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| CL2010001538A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular. | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| CR20110639A (es) | Mutantes fgf21 y usos de los mismos | |
| BR112017001162A2 (pt) | métodos para tratar paramixovírus | |
| BR112019003785A2 (pt) | tabaco resistente a vírus e método de melhoramento para o mesmo | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |